No photo of John W Regan

View Scopus Profile

John W Regan

  • 8651 Citations
  • 48 h-Index
1974 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where John W Regan is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

Adrenergic Receptors Medicine & Life Sciences
Prostaglandins Medicine & Life Sciences
Dinoprostone Medicine & Life Sciences
Ligands Medicine & Life Sciences
Receptors, Prostaglandin E, EP2 Subtype Medicine & Life Sciences
Dinoprost Medicine & Life Sciences
Receptors, Prostaglandin E, EP4 Subtype Medicine & Life Sciences
Prostaglandin Receptors Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 1991 2008

ALPHA 2 AND PROSTAGLANDIN RECEPTORS IN EYE

Regan, J. W.

National Institutes of Health

4/1/97 → 3/31/08

Project: Research project

Prostaglandin Receptors
Aquaporin 1
Aquaporins
Epithelium
Protein Isoforms

CLONING AND MUTAGENESIS OF A2 - ADRENERGIC RECEPTORS

Regan, J. W.

National Institutes of Health

4/1/91 → 3/31/97

Project: Research project

Mutagenesis
Adrenergic Receptors
Organism Cloning
varespladib methyl
Adrenergic Agents

Research Output 1974 2019

  • 8651 Citations
  • 48 h-Index
  • 138 Article
  • 1 Book
1 Citation (Scopus)

Short chain fatty acid butyrate uptake reduces expressions of prostanoid EP 4 receptors and their mediation of cyclooxygenase-2 induction in HCA-7 human colon cancer cells

Kurata, N., Tokashiki, N., Fukushima, K., Misao, T., Hasuoka, N., Kitagawa, K., Mashimo, M., Regan, J. W., Murayama, T. & Fujino, H., Jun 15 2019, In : European Journal of Pharmacology. 853, p. 308-315 8 p.

Research output: Contribution to journal › Article

Volatile Fatty Acids
Butyrates
Cyclooxygenase 2
Colonic Neoplasms
Prostaglandins
1 Citation (Scopus)

Cellular density-dependent increases in HIF-1α compete with c-Myc to down-regulate human EP4 receptor promoter activity through Sp-1-binding region

Seira, N., Yamagata, K., Fukushima, K., Araki, Y., Kurata, N., Yanagisawa, N., Mashimo, M., Nakamura, H., Regan, J. W., Murayama, T. & Fujino, H., Dec 1 2018, In : Pharmacology research & perspectives. 6, 6, p. e00441

Research output: Contribution to journal › Article

Homeostasis
Down-Regulation
Colonic Neoplasms
Carcinogenesis
Luciferases

Anti-cancer effects of MW-03, a novel indole compound, by inducing 15-hydroxyprostaglandin dehydrogenase and cellular growth inhibition in the ls174t human colon cancer cell line

Seira, N., Yanagisawa, N., Suganami, A., Honda, T., Wasai, M., Regan, J. W., Fukushima, K., Yamaguchi, N., Tamura, Y., Arai, T., Murayama, T. & Fujino, H., 2017, In : Biological and Pharmaceutical Bulletin. 40, 10, p. 1806-1812 7 p.

Research output: Contribution to journal › Article

15-hydroxyprostaglandin dehydrogenase
Colonic Neoplasms
Cell Line
Growth
Dinoprostone
3 Citations (Scopus)

PGE1 and E3 show lower efficacies than E2 to β-catenin-mediated activity as biased ligands of EP4 prostanoid receptors

Araki, Y., Suganami, A., Endo, S., Masuda, Y., Fukushima, K., Regan, J. W., Murayama, T., Tamura, Y. & Fujino, H., 2017, (Accepted/In press) In : FEBS Letters.

Research output: Contribution to journal › Article

Receptors, Prostaglandin E, EP4 Subtype
Catenins
Alprostadil
Ligands
Dinoprostone
1 Citation (Scopus)

Human DP and EP2 prostanoid receptors take on distinct forms depending on the diverse binding of different ligands

Suganami, A., Fujino, H., Okura, I., Yanagisawa, N., Sugiyama, H., Regan, J. W., Tamura, Y. & Murayama, T., Nov 1 2016, In : FEBS Journal. 283, 21, p. 3931-3940 10 p.

Research output: Contribution to journal › Article

Prostaglandins
Ligands
Dinoprostone
Prostaglandin D2
Receptors, Prostaglandin E, EP2 Subtype